tbuckley/cabot-search huggingface dataset:
Abstract 15293: Increased Level of Cardiac Troponin T is a Clue of Cardiac Amyloidosis in Patients With Myocardial Hypertrophy
Authors: Seiji Takashio, Megumi Yamamuro, Toshihisa Anzai, Hisao Ogawa
Journal: Circulation (2014)

Background: Cardiac amyloidosis (CA) is an important differential diagnosis in patients with myocardial hypertrophy. The precise diagnosis of CA requires endomyocardial biopsy to demonstrate amyloid deposition, but this procedure is relatively invasive and cannot be performed routinely. Therefore, it is important to increase pretest probability of CA in patients with myocardial hypertrophy by noninvasive modalities. Because it is well known that cardiac troponin level is elevated in patients with CA, we hypothesized that increased level of cardiac troponin T contributes to diagnosis of CA in patients with myocardial hypertrophy using high sensitive assay (hs-TnT). Methods and Results: Among nonischemic patients with myocardial hypertrophy (interventricular septal thickness≧ 12 mm), hs-TnT level was measured in 28 CA patients (senile systemic amyloidosis: 13, AL amyloidosis: 14, familial amyloidosis: 1) proven amyloidosis pathologically and 29 non-CA patients proven by endomyocardial biopsy. It was significantly higher in CA patients than non-CA patients (0.075 [0.047-0.116] ng/ml vs. 0.013 [0.009-0.019] ng/ml; p&lt;0.001: Figure). Receiver operating characteristic analysis selected 0.030 ng/ml as the best cutoff value of diagnosis for CA, with a sensitivity and specificity of 96% and 93%, respectively and area under the curve of 0.98 (95% confidence interval 0.94 to 1.00, p&lt;0.001). Conclusions: Increased level of hs-TnT (&gt;0.030 ng/ml) is highly suggestive of CA in patients with myocardial hypertrophy. These patients need additional diagnostic approach for CA.
Modifiable risk factors in periodontal disease
Authors: Silvana P. Barros, Steven Offenbacher
Journal: Periodontology 2000 (2013)

Abstract Epigenetics as a modifiable risk factor in periodontal diseases has been investigated in light of the current knowledge of how chronic infection and inflammation can affect gene‐specific epigenetic reprogramming in periodontal tissues. Epigenomic programming might be particularly sensitive to environmental influences, and a combination of physiological stressors and environmental exposures appears to affect the epigenomic program acquired by a cell during differentiation and throughout the cellular lineage lifespan. Viral and bacterial infections can establish several types of epigenetic modifications, which sometimes engage in a complex epigenetic crosstalk also reflecting in the establishment and progress of periodontal diseases. The inflammatory and metabolic states of the periodontal tissues are driven by the infectious stimuli, and the magnitude of the cellular and molecular signature response is further dictated by the host genetic and epigenetic traits associated with various systemic exposures, including smoking, obesity and diabetes/hyperglycemia. This review discusses the advances in epigenetics, focusing on the role of DNA methylation in the pathogenesis of periodontal disease and the potential of epigenetic therapy.
Atlas of Gastrointestinal Endoscopy
Authors: Fred E. Silverstein, G. N. J. Tytgat
Journal: Annals of Internal Medicine (1992)

The normal gastrointestinal tract esophagus I - diverticula, hiatal hernias, webs, rings, reflux, and Barrett's metaplasia esophagus II - neoplasms, infections, and involvement in graft-versus-host disease esophagus III - motor dysfunction, vascular abnormalities and postoperative evaluation stomach I - gastric ulcers, anatomic and vascular abnormalities, and postoperative evaluation stomach II - tumours and polyps stomach III - gastritis and upper gastrointestinal bleeding small bowel endoscopic retrograde cholangiopancreatography and sphincterotomy colon I - polyps and tumors colon II - inflammatory and infectious disorders colon III - diverticular disease, vascular malformations and other colonic abnormalities.
Apologies of a Medical Manuscript
Authors: Mark Kliewer
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P4-04-27: Chemokines released by breast cancer-associated fibroblasts induce epithelial to mesenchymal transition in MCF7 breast cancer cells
Authors: Patsy S Soon, Edward Kim, Diana E Benn, Robert Baxter
Journal: Cancer Research (2015)

Abstract Purpose: The tumour microenvironment plays a critical role in tumour progression, with cancer-associated fibroblasts (CAFs) in particular being involved in this process (1). Treating breast cancer cells with conditioned media from CAFs has been shown to induce epithelial-mesenchymal transition (EMT) of the breast cancer cells compared to conditioned media from normal breast fibroblasts (NBFs) (2). This study aims to identify factors released by CAFs which induce EMT in breast cancer cells. Methodology: Primary cultures of six pairs of CAFs and NBFs were established from breast cancer patient samples. Serum-free conditioned media from these cells were collected for chemokine array analysis. MCF7 breast cancer cells were treated with recombinant chemokines and their corresponding receptor antagonists. Vimentin levels, as determined by immunoblot, and cell invasiveness, as measured by transwell assay, were used as indicators of EMT. Results: Chemokine array showed that CAFs secreted more CXCL1, CXCL8, CXCL12 and CCL2 compared to matched NBFs. Recombinant CXCL8, CXCL12 and CCL2, but not CXCL1, were able to induce vimentin and to increase invasiveness in MCF7 cells. Antagonists for receptors of CXCL8, CXCL12 and CCL2 counteracted the effect of EMT induction on MCF7 cells by recombinant chemokines. Conclusion: CXCL8, CXCL12 and CCL2, which are secreted at higher levels by CAFs compared to NBFs, induced EMT and increased invasiveness in MCF7 cells. These results suggest that therapeutic targeting of these chemokines or their receptors may be inhibitory to metastasis in some breast cancers. References: 1. Bhowmick, N A et al. (2004) Nature 432, 332-337 2. Soon, P S et al. (2013) Endocr Relat Cancer 20, 1-12. Citation Format: Patsy S Soon, Edward Kim, Diana E Benn, Robert Baxter. Chemokines released by breast cancer-associated fibroblasts induce epithelial to mesenchymal transition in MCF7 breast cancer cells [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-04-27.
Educational Epidemiology—Reply
Authors: Patricia A. Carney, Catherine F. Pias, David W. Nierenberg, W. Blair Brooks, Therese A. Stukel, Adam Keller
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Nodal Mikrometastazların Tanısında Pragmatik Bir Yaklaşım
Authors: Esther Herpel, Thomas Muley, Thomas Schneider, Elisa Palm, Dörthe Kieslich de Hol, student, Arne Warth, Michael Meister, Konstantina Storz, Philipp A. Schnabel, Peter Schirmacher, Hendrik Dienemann, Hans Hoffmann
Journal: Journal of Thoracic Oncology (2010)
First International New Intravascular Rigid-Flex Endovascular Stent Study (FINESS): Clinical and Angiographic Results After Elective and Urgent Stent Implantation fn1fn1This study was supported in part by a grant from Medinol, Ltd., Kiryat Atidim, Tel Aviv, Israel.
Authors: Yaron Almagor, Steven Feld, Ferdinand Kiemeneij, Patrick W. Serruys, Marie-Claude Morice, Antonio Colombo, Carlos Macaya, Jean L. Guermonprez, Jean Marco, Raimund Erbel, Ian M. Penn, Raoul Bonan, Martin B. Leon
Journal: Journal of the American College of Cardiology (1997)
Abstract 15745: Tenascin-c Levels and Clinical Importance in Pulmonary Arterial Hypertension
Authors: Ozcan Vuran, Meral L Kayikcioglu, Sanem Nalbantgil, Ogtay Musayev, Hatice S Kemal, Nesrin Mogulkoc, Levent H Can, Kadir H Kultursay
Journal: Circulation (2014)

Background: Prognostic markers are known to have an important value in guiding treatment of pulmonary arterial hypertension (PAH) which is associated with high mortality and morbidity. The prognostic importance of some biomarkers like BNP has been shown and used in the routine course of PAH. Tenacsin-C (TNC) is a glycoprotein located in the extracellular matrix which has an important role in PAH pathophysiology. However, the clinical relevance of PAH and TNC is unknown. In this study, we investigated the plasma levels of TNC in patients with PAH as a possible prognostic marker. Methods: Study population consisted of 45 PAH (29 women, mean age: 32±9 years, 34 with PAH associated with congenital heart disease, 9 idiopathic PAH and 2 chronic thromboembolic pulmonary hypertension) patients who were followed-up in our PAH centre. Twenty age-sex matched healthy subjects served as the control-group. Plasma TNC levels were measured using ELISA-method. All patients were evaluated with transthoracic echocardiography including assessment of right ventricle, six minute walk test, and NT-proBNP levels simultaneously, which are all known to have prognostic value in PAH. Data were comparatively evaluated using appropriate statistical analysis. Results: TNC levels in patients with PAH were significantly higher, compared to healthy controls (61.9±20.7 ng/mL versus 12.6±5.6 ng/mL, respectively, p&lt;0.0001). There was no significant relationship between age, gender, and TNC levels. There was a significant positive correlation between TNC levels in PAH group and functional class (rho=0.355, p=0.017) and NT-proBNP (rho=0.5, p=0.001) levels, whereas there was a significant negative correlation between TNC levels and fractional area change (FAC, rho=-0.33, p=0.035) and tricuspid annular plane systolic excursion (TAPSE, rho=-0.495, p=0.006). Conclusions: TNC levels are substantially increased in PAH. There is a significant association between TNC levels and parameters with proved prognostic value in PAH, such as functional class, TAPSE, FAC, and NT-proBNP levels. All of these data suggest that TNC levels in patients with PAH may be a new prognostic biomarker. Further prospective studies are needed to confirm this statement.
Abstract 16291: Comparing Predictors of Heart Failure and Cancer Caregiver Satisfaction with Hospice Care
Authors: Meredith A MacKenzie, Harleah G Buck, Salimah H Meghani, Barbara Riegel
Journal: Circulation (2014)

Introduction:  Heart failure patients are increasingly enrolling in hospice care, along with their informal caregivers. While caregiver satisfaction with hospice influences both patient and caregiver outcomes, we know little about predictors of caregiver satisfaction. Secondly, previous research has been done almost exclusively in the cancer population.   Objective:  Our aim was to identify predictors of caregiver satisfaction, then explore whether predictors differ between heart failure and cancer caregivers.   Methods:  This was a retrospective cohort study of national data collected in 2011 by the National Hospice and Palliative Care Organization using the Family Evaluation of Hospice Care (FEHC). We drew stratified random samples (n=1000 each) from the available FEHC responses of adult heart failure (n=19,818) and cancer (n=70,782) caregivers. We used multiple linear regression to examine the relationship between possible predictors and caregiver satisfaction. Predictors examined included caregiver and patient demographics, clinical characteristics and hospice characteristics.   Results:  In the heart failure cohort, caregiver age, relationship, patients’ symptoms, and caregiver education predicted satisfaction (p   Conclusions:  Hospices should seek to identify and further support vulnerable caregivers. Particular attention needs to be devoted to identifying and managing patient symptoms to the satisfaction of caregivers.
Abstract 16491: Predictors of Incident Conduction System Disease in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Authors: Thomas A Dewland, Elsayed Z Soliman, Barry R Davis, Jared W Magnani, Jose-Miguel Yamal, Linda B Piller, L. Julian Haywood, Gregory M Marcus
Journal: Circulation (2014)

Introduction: Left and right bundle branch block (L and RBBB) have been associated with heightened morbidity and mortality, but risk factors for incident conduction disease remain unknown. Understanding factors that accelerate or delay conduction abnormalities could help identify therapies to treat or prevent this condition. Hypothesis: Clinical variables associated with myocardial fibrosis will increase conduction system disease risk while treatment with lisinopril (an anti-fibrotic) will reduce this risk. Methods: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial was a double-blind clinical trial that randomized 33,357 hypertensive participants ≥ 55 years of age with at least one other cardiovascular risk factor to treatment with amlodipine, lisinopril, or chlorthalidone. An electrocardigram (ECG) was obtained at study enrollment and at every two years of follow up. Conduction system disease was defined as LBBB, RBBB, intraventricular conduction delay, or 1st degree AV block. Participants without a baseline or follow up ECG (n=4,510) or with baseline conduction disease (n=6,181) were excluded. Cox proportional hazards models were used to examine predictors of incident disease. Results: Among 21,129 participants without prevalent conduction disease, 444 developed LBBB, 608 developed RBBB, and 1,138 developed any conduction defect during a mean 5.0 ± 1.2 years of follow up. Several factors were significantly associated with incident disease (Figure). Compared to chlorthalidone, lisinopril was associated with a significant 19% reduction in conduction abnormalities (HR 0.81, 95% CI 0.69-0.95). Conclusions: Incident conduction system disease is independently associated with multiple clinical factors and is significantly reduced by lisinopril therapy. Further studies are warranted to determine if pharmacologic treatment can impact conduction abnormality outcomes, including pacemaker implantation.
Low-Carb, Low-Fat Diet Gurus Face Off
Authors: Joan Stephenson
Journal: JAMA (2003)

LAST SUMMER, AN ARTICLE IN THE July 7 New York Times Sunday Magazine challenged conventional thinking about weight loss, questioning the efficacy of low-fat diets and sparking a resurgence of interest in socalled high-protein or low-carbohydrate diets. In this issue of JAMA (page 1837), a systematic review of studies published between 1966 and February 2003 on the safety and efficacy of lowcarbohydrate diets finds that there is insufficient evidence to recommend or advise against the use of such diets, and that weight loss was associated with length of the diet, prediet weight, and the number of calories consumed, but not reduced carbohydrate content. JAMA asked proponents of lowcarbohydrate and low-fat diets, and an obesity researcher who has explored many interventions, to comment on weight loss approaches and the obesity epidemic.
Surgical Mortality, Hospital Quality, and Small Sample Size
Authors: Mayer Brezis, Avraham Oren
Journal: JAMA (2005)

In Reply: We strongly endorse the use of direct generic substitution and “rational prescribing” when they are based on rigorous scientific information, because these are important ways to help people manage their drug expenditures. This is based on our own finding that seniors who exceeded their drug benefit caps decreased their use of essential medications, as well as on estimates from others that 1 in 4 Medicare beneficiaries will face the “donut hole” in the new Medicare drug benefit. This “donut hole” represents the gap in coverage when beneficiaries’ annual drug expenditures exceed their benefit cap but are not yet high enough to qualify for catastrophic coverage. Better mechanisms to help people manage their drug costs must be found. We thank Drs Bjarnason and Kampmann for highlighting these programs in Denmark. Currently, all 50 states in the United States allow pharmacists to make direct generic substitutions unless directly prohibited by clinicians on the prescription. We support the additional development of evidence-based guidelines that take into account cost as well as safety and effectiveness to help clinicians and patients choose medications. However, transparency to both the patient and the clinician regarding potential cost-effectiveness trade-offs is essential. In the United States, health plans, insurers, and pharmacy benefit managers often send information to clinicians and patients to increase their awareness of drug costs and effectiveness. Other sources such as the treatment guidelines from The Medical Letter on Drugs and Therapeutics and from the State of Oregon have also added cost information to independent comparisons of drug effectiveness and safety. Further work is needed to ensure consistency among these guides and to help patients and clinicians use these tools in daily practice so that a patient’s health is optimized at the price that he or she is willing to pay.
ACUTE HEMOLYTIC ANEMIA WITH AUTO-AGGLUTINATION FOLLOWING SULFONAMIDE THERAPY
Authors: William Levison
Journal: Annals of Internal Medicine (1947)

Case Reports1 December 1947ACUTE HEMOLYTIC ANEMIA WITH AUTO-AGGLUTINATION FOLLOWING SULFONAMIDE THERAPYWILLIAM LEVISONWILLIAM LEVISONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-27-6-1034 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe following case is reported because it represents a rare phenomenon previously described as a complication of sulfonamide therapy and as a potential source of error in blood typing.A 23 year old soldier was admitted on January 7, 1945 with a gunshot wound through the left abdomen. Laparotomy revealed transsection of the jejunum in two places and a perforation of the stomach. The exit wound was in the left lumbar region. The perforations of the stomach were sutured, the involved jejunum resected, and an end-to-end anastomosis done. Approximately 2,000 c.c. of blood were found in the peritoneal cavity. Four...Bibliography1. ANTOPOLAPPLEBAUMGOLDMAN WIL: Two cases of acute hemolytic anemia with auto-agglutination following sulfanilamide therapy, Jr. Am. Med. Assoc., 1939, cxiii, 448. Google Scholar2. DAMESHEK W: Cold hemagglutinins in acute hemolytic reactions in association with sulfonamide medication and infection, Jr. Am. Med. Assoc., 1943, cxxiii, 77. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication July 11, 1946. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1947Volume 27, Issue 6Page: 1034-1036KeywordsBloodFirearm injuriesHemolytic anemiaJejunumLaparotomyStomachSulfonamide ePublished: 1 December 2008 Issue Published: 1 December 1947 PDF downloadLoading ...
Improved identification of von Hippel-Lindau gene mutations in sporadic kidney tumors by parallel endonuclease scanning and DNA sequencing
Authors: Michael L. Nickerson, Stan Lilleberg, Jeffrey A. Durocher
Journal: Clinical Cancer Research (2006)

A36   Mutation of the von Hippel-Lindau (VHL) tumor suppressor gene has been implicated in the pathogenesis of clear cell renal cell carcinoma (RCC). A large case-control epidemiology study of kidney cancer is underway in Eastern Europe, which will examine how exposure history relates to the spectrum of VHL mutations. Three methods of mutation detection were initially compared: denaturing high performance liquid chromatography (DHPLC), double-stranded (ds) sequencing, and endonuclease scanning. Endonuclease scanning was as sensitive as DHPLC and provided additional detail about the location of a variant/mutation in an amplicon. An approach using both endonuclease scanning and ds sequencing was then applied to analysis of VHL in 205 tumors from Eastern European patients with sporadic clear cell RCC. Using these two methods, 171/205 tumors (83.4%) were VHL mutation positive. An unexpectedly high proportion of mutations (45%) were difficult to detect by ds sequencing alone. PCR products were re-amplified from 91 tumors using a proofreading polymerase and endonuclease digests showed 100% agreement with the original data set. Analysis of endonuclease digests on a 96 well capillary electrophoresis instrument was amendable to high sample throughput that matched ds sequencing. Significantly, endonuclease scanning dramatically reduced staff time required for manual review of sequencing chromatograms. These two methods are complementary and sensitive, and can be used to meet current demand for large scale genetic analysis of patient tumor samples to detect somatic and inherited mutations relevant to personalized medicine.
Abstract 2461: Therapeutic Hypothermia During CPR Reduces Myocardial Ischemic Injury
Authors: Shijie Sun, Giuseppe Ristagno, Fengqing Song, Yongqin Li, Tao Yu, Yi Shan, Max H Weil, Wanchun Tang
Journal: Circulation (2009)

Therapeutic hypothermia following return of spontaneous circulation (ROSC) improves neurological outcome and survival. In the present study, we examined the effects of therapeutic hypothermia initi...
VASCULITIS IN ASSOCIATION WITH AUSTRALIA ANTIGEN
Authors: David J. Gocke, Konrad Hsu, Councilman Morgan, Stepheno Bombardieri, Michael Lockshin, Charles L. Christian
Journal: The Journal of Experimental Medicine (1971)

Six patients with biopsy-proven polyarteritis nodosa and chronic Australia antigenemia are described. Evidence was found in these patients for the presence of circulating immune complexes composed of Australia antigen and immunoglobulin. In addition, in two patients immunofluorescent studies localized Australia antigen, IgM, and complement in the blood vessel walls.